Roche oncology chief sees big impact of sugar tech

Three years after plunking down $180 million to buy GlycArt, Roche says the sugar-related technology it acquired in the deal is demonstrating striking effectiveness enhancing experimental cancer therapies. The glycol-engineering tech changes the structure of sugars that coat antibodies, improving new therapies that prod the human immune system to attack cancer cells. Roche's chief of oncology drug development, David Heimbrook, noted that investigators saw the technology at work in mice studies of R7159, which has now entered the clinic.

"The important outcome was that we saw almost complete inhibition of tumor growth," Heimbrook told reporters in New York.

- check out the report from Forbes

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.